Role of anti-vimentin antibodies in allograft rejection

Human Immunology

Volumn 74, Issue 11, 2013, Pages 1459-1462

  Rose, Marlene L ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI VIMENTIN ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG; VIMENTIN;

ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CONFOCAL MICROSCOPY; DRUG EFFECT; ENDOTHELIUM CELL; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE FILAMENT; KIDNEY TRANSPLANTATION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; THROMBOCYTE;

AMR; ANTI-VIMENTIN ANTIBODIES; ANTIBODY MEDIATED REJECTION; AVA; CFA; COMPLETE FREUND'S ADJUVANT; HMEC; HUMAN MICROVASCULAR ENDOTHELIAL CELLS; MMF; MYCOPHENOLATE MOFETIL; PAF; PLATELET ACTIVATING FACTOR;

ANIMALS; ANTIBODIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MICE; MODELS, ANIMAL; POSTOPERATIVE COMPLICATIONS; PRIMATES; TRANSPLANTATION IMMUNOLOGY; VIMENTIN;

EID: 84885030653     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.06.006     Document Type: Article

References (36)

1. Thebault S., Gilbert D., Hubert M., Drouot L., Machour N., Lange C., et al. Orderly pattern of development of the autoantibody response in (New Zealand White x BXSB) F1 lupus mice: characterization of target antigens and antigen spreading by two-dimensional gel electrophoresis and mass spectrometry. J Immunol 2002, 169:4046-4053.
2. Vossenaar E.R., Despres N., Lapointe E., Van der H.A., Lora M., Senshu T., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142-R150.
3. Azimzadeh A.M., Pfeiffer S., Wu G.S., Schroder C., Zhou H., Zorn G.L., et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005, 5:2349-2359.
4. Jonker M., Danskine A., Haanstra K., Wubben J., Kondova I., Kuhn E.M., et al. The autoimmune response to vimentin after renal transplantation in nonhuman primates is immunosuppression dependent. Transplantation 2005, 80:385-393.
5. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71:886-892.
6. Boilard E., Bourgoin S.G., Bernatchez C., Surette M.E. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 2003, 102:2901-2909.
7. Moisan E., Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol 2006, 79:489-498.
8. Morishima N. Changes in nuclear morphology during apoptosis correlate with vimentin cleavage by different caspases located either upstream or downstream of Bcl-2 action. Genes Cells 1999, 4:401-414.
9. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
10. Rosen A., Casciola-Rosen L.A. Autoantigen as substrates for apoptopic proteases:implications for the pathogenesis of systemic autoimmune diseases. Cell Death Diff 1999, 6:6-12.
11. Mor-Vaknin N., Punturieri A., Sitwala K., Markovitz D.M. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003, 5:59-63.
12. Podor T.J., Singh D., Chindemi P., Foulon D.M., McKelvie R., Weitz J.I., et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002, 277:7529-7539.
13. Xu B., DeWaal R.M., Mor-Vaknin N., Hibbard C., Markovitz D.M., Kahn M.L. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol 2004, 24:9198-9206.
14. Keuschnigg J., Henttinen T., Auvinen K., Karikoski M., Salmi M., Jalkanen S. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood 2009, 114:478-484.
15. Nieminen M., Henttinen T., Merinen M., Marttila-Ichihara F., Eriksson J.E., Jalkanen S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol 2006, 8:156-162.
16. Niemela H., Elima K., Henttinen T., Irjala H., Salmi M., Jalkanen S. Molecular identification of PAL-E, a widely used endothelial-cell marker. Blood 2005, 106:3405-3409.
17. Jaalouk D.E., Ozawa M.G., Sun J., Lahdenranta J., Schlingemann R.O., Pasqualini R., et al. The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1. Cancer Res 2007, 67:9623-9629.
18. Bilalic S., Michlmayr A., Gruber V., Buchberger E., Burghuber C., Bohmig G.A., et al. Lymphocyte activation induces cell surface expression of an immunogenic vimentin isoform. Transpl Immunol 2012, 27:101-106.
19. Bang H., Egerer K., Gauliard A., Luthke K., Rudolph P.E., Fredenhagen G., et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56:2503-2511.
20. Ohsaki H., Hirakawa E., Nakamura M., Norimatsu Y., Kiyomoto H., Haba R. Expression of vimentin and high-molecular-weight cytokeratin (clone 34ssE12) in differentiating reactive renal tubular cells from low-grade urothelial carcinoma cells in voided urine. Cytopathology 2011, 22:247-252.
21. Vansthertem D., Gossiaux A., Decleves A.E., Caron N., Nonclercq D., Legrand A., et al. Expression of nestin, vimentin, and NCAM by renal interstitial cells after ischemic tubular injury. J Biomed Biotechnol 2010, 2010:193259.
22. Nath D.S., Ilias B.H., Tiriveedhi V., Alur C., Phelan D., Ewald G.A., et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010, 29:1277-1285.
23. Barber L.D., Whitelegg A., Madrigal J.A., Banner N.R., Rose M.L. Detection of vimentin-specific autoreactive CD8+ T cells in cardiac transplant patients. 2. Transplantation 2004, 77:1604-1609.
24. Carter V., Shenton B.K., Jaques B., Turner D., Talbot D., Gupta A., et al. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005, 37:654-657.
25. Bilalic S., Veitinger M., Ahrer K.H., Gruber V., Zellner M., Brostjan C., et al. Identification of Non-HLA antigens targeted by alloreactive antibodies in patients undergoing chronic hemodialysis. J Proteome Res 2010, 9:1041-1049.
26. Rose M.L., Smith J., Dureau G., Keogh A., Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002, 21:282-285.
27. Mahesh B., Leong H.S., McCormack A., Sarathchandra P., Holder A., Rose M.L. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007, 170:1415-1427.
28. Fedoseyeva E.V., Zhang F., Orr P.L., Levin D., Buncke H.J., Benichou G. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999, 162:6836-6842.
29. Fedoseyeva E.V., Kishimoto K., Rolls H.K., Illigens B.M., Dong V.M., Valujskikh A., et al. Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. J Immunol 2002, 169:1168-1174.
30. Haque M.A., Mizobuchi T., Yasufuku K., Fujisawa T., Brutkiewicz R.R., Zheng Y., et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002, 169:1542-1549.
31. Baldwin W.M., Qian Z., Ota H., Samaniego M., Wasowska B., Sanfilippo F. Complement as a mediator of vascular inflammation and activation in allografts. J Heart Lung Transplant 2000, 19:723-730.
32. Leong H.S., Mahesh B.M., Day J.R., Smith J.D., McCormack A.D., Ghimire G., et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008, 83:263-271.
33. Kuo H.H., Morrell C.N., Baldwin W.M. Alloantibody induced platelet responses in transplants: potent mediators in small packages. Hum Immunol 2012.
34. Mahesh B., Leong H.S., Nair K.S., McCormack A., Sarathchandra P., Rose M.L. Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation 2010, 90:4-13.
35. Labarrere C.A., Nelson D.R., Faulk W.P. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 1998, 105:207-213.
36. Labarrere C.A., Pitts D., Nelson D.R., Faulk W.P. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 1995, 333:1111-1116.